Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen
Erschienen in:

07.02.2020 | Originalien

Moderne Behandlungsoptionen des sekundären Hyperparathyreoidismus vor dem Hintergrund kardiovaskulärer Kalzifizierung

verfasst von: OA PD Dr. Emanuel Zitt

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der sekundäre Hyperparathyreoidismus (sHPT) hat unbehandelt deletäre Auswirkungen auf verschiedene Organsysteme. Insbesondere die kardiovaskuläre Kalzifizierung als Folge der mit dem sHPT einhergehenden Veränderungen des Knochen- und Mineralstoffwechsels und der zu dessen Therapie eingesetzten medikamentösen Interventionen ist in den Mittelpunkt der Forschung und Behandlungskonzepte gerückt. Sämtliche eingesetzten Therapien sind effektiv im Hinblick auf eine Korrektur der laborchemisch fassbaren Veränderungen im Rahmen des sHPT, aber nur sehr wenige auch klinisch in ihrer Auswirkung auf die kardiovaskuläre Kalzifizierung und patientenbezogene Endpunktdaten (Mortalität, kardiovaskuläre Morbidität) in aussagekräftigen Studien untersucht. Die geringe Anzahl qualitativ hochwertiger randomisierter kontrollierter Studien darf nicht zu einem nihilistischen Ansatz führen. Aufgrund unzureichender Daten ist keine der Therapieoptionen (Phosphatbinder, Substitution mit nativem Vitamin D oder Calcitriol und Analoga, Kalzimimetikum, Parathyreoidektomie) prinzipiell den anderen überlegen, wenn auch patienten- und situationsbezogen Vorteile für die eine oder andere Therapie bestehen. Ein breiteres therapeutisches Fenster verlangt oft eine Kombination dieser Behandlungsoptionen und eine Individualisierung der sHPT-Therapie.
Vorheriger Artikel Osteoporose bei Nierenerkrankung
Nächster Artikel Mitteilungen des Magnesiumforum Bad Radkersburg
Literatur
1.
Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921PubMed
2.
Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W et al (2019) Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun 10:4693PubMedPubMedCentral
3.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMed
4.
Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK et al (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695–701PubMed
5.
Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C et al (1998) Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037–2040PubMed
6.
Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24:1506–1523PubMed
7.
Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE (2009) The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 53:2129–2140PubMed
8.
Malluche H, Faugere MC (1990) Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 38:193–211PubMed
9.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953PubMed
10.
Zitt E, Neyer U (2011) Management of secondary hyperparathyroidism in hemodialysis patients. In: Carpi A (Hrsg) Progress in hemodialysis—from emergent biotechnology to clinical practic: intech, S 331–348
11.
Briet M, Burns KD (2012) Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin Sci (Lond) 123:399–416
12.
Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS et al (2009) Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20:381–387PubMedPubMedCentral
13.
Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E (2005) Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68:429–436PubMed
14.
Vervloet M, Cozzolino M (2017) Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int 91:808–817PubMed
15.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617PubMed
16.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMed
17.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7:1–59
18.
Barreto FC, Barreto DV, Massy ZA, Drueke TB (2019) Strategies for phosphate control in patients with CKD. Kidney Int Rep 4:1043–1056PubMedPubMedCentral
19.
Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP et al (2008) Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88:1511–1518PubMedPubMedCentral
20.
Lacson E Jr., Ikizler TA, Lazarus JM, Teng M, Hakim RM (2007) Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr 17:363–371PubMed
21.
Zitt E, Lamina C, Sturm G, Knoll F, Lins F, Freistatter O et al (2011) Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients. Clin J Am Soc Nephrol 6:2650–2656PubMedPubMedCentral
22.
Sherman RA, Mehta O (2009) Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. Am J Kidney Dis 54:18–23PubMed
23.
Sherman RA, Mehta O (2009) Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol 4:1370–1373PubMedPubMedCentral
24.
Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D et al (2009) Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 301:629–635PubMed
25.
Noori N, Kalantar-Zadeh K, Kovesdy CP, Bross R, Benner D, Kopple JD (2010) Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin J Am Soc Nephrol 5:683–692PubMedPubMedCentral
26.
Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K et al (2009) Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20:388–396PubMedPubMedCentral
27.
Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM et al (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407–1415PubMedPubMedCentral
28.
Goldsmith D, Ritz E, Covic A (2004) Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 66:1315–1333PubMed
29.
Cozzolino M, Mazzaferro S, Brandenburg V (2011) The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant 26:402–407PubMed
30.
Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252PubMed
31.
Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A et al (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68:1815–1824PubMed
32.
Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF (2009) Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 54:619–637PubMed
33.
Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA et al (2008) A 1‑year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the calcium acetate renagel evaluation‑2 (CARE-2) study. Am J Kidney Dis 51:952–965PubMed
34.
Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 7:487–493PubMed
35.
Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D et al (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62:771–778PubMed
36.
Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L et al (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130–1137PubMed
37.
38.
Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW (2008) A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3:1131–1138PubMedPubMedCentral
39.
40.
Lenglet A, Liabeuf S, Esper NE, Brisset S, Mansour J, Lemaire-Hurtel AS et al (2017) Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant 32:1597PubMed
41.
Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Astrand M, Johansson S, Knutsson M et al (2017) Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol 28:1933–1942PubMedPubMedCentral
42.
Block GA, Rosenbaum DP, Yan A, Chertow GM (2019) Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol 30:641–652PubMedPubMedCentral
43.
Friedl C, Zitt E (2017) Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis 10:109–122PubMedPubMedCentral
44.
Zitt E, Sprenger-Mahr H, Mundle M, Lhotta K (2015) Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency. BMC Nephrol 16:128PubMedPubMedCentral
45.
Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R et al (2016) Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol 44:316–325PubMed
46.
Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D et al (2008) Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74:1070–1078PubMed
47.
Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456PubMed
48.
Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr. et al (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125PubMed
49.
Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB et al (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858–1865PubMed
50.
Koller H, Zitt E, Staudacher G, Neyer U, Mayer G, Rosenkranz AR (2004) Variable parathyroid hormone(1-84)/carboxylterminal PTH ratios detected by 4 novel parathyroid hormone assays. Clin Nephrol 61:337–343PubMed
51.
Souberbielle JC, Roth H, Fouque DP (2010) Parathyroid hormone measurement in CKD. Kidney Int 77:93–100PubMed
52.
53.
Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J (2000) Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 11:903–911PubMed
54.
Meola M, Petrucci I, Barsotti G (2009) Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 24:982–989PubMedPubMedCentral
55.
Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG et al (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95:4040–4045PubMedPubMedCentral
56.
Urena P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N et al (2009) Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice—the ECHO observational study. Nephrol Dial Transplant 24:2852–2859PubMed
57.
Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R et al (2017) Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 317:146–155PubMed
58.
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525PubMed
59.
Zitt E, Fouque D, Jacobson SH, Malberti F, Ryba M, Urena P et al (2013) Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J 6:287–294PubMedPubMedCentral
60.
Sprague SM, Evenepoel P, Curzi MP, Gonzalez MT, Husserl FE, Kopyt N et al (2009) Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 4:1465–1476PubMedPubMedCentral
61.
Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800PubMed
62.
Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K et al (2010) Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78:578–589PubMed
63.
Friedl C, Reibnegger G, Kramar R, Zitt E, Pilz S, Mann JFE et al (2017) Mortality in dialysis patients with cinacalcet use: a large observational registry study. Eur J Intern Med 42:89–95PubMed
64.
EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494
65.
Aladren Regidor MJ (2009) Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clin Nephrol 71:207–213PubMed
66.
Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D et al (2005) 1,25-Dihydroxyvitamin D3 but not cinacalcet Hcl (sensipar/mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20:1370–1377PubMed
67.
Lopez I, Mendoza FJ, Guerrero F, Almaden Y, Henley C, Aguilera-Tejero E et al (2009) The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol 296:F1376–1385PubMed
68.
Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K et al (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327–1339PubMed
69.
Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB et al (2017) Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 317:156–164PubMed
70.
Yu L, Tomlinson JE, Alexander ST, Hensley K, Han CY, Dwyer D et al (2017) Etelcalcetide, a novel calcimimetic, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism. Calcif Tissue Int 101:641–653PubMedPubMedCentral
71.
Friedl C, Zitt E (2018) Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. Drug Des Devel Ther 12:1589–1598PubMedPubMedCentral
72.
Zitt E, Konig M, Vychytil A, Auinger M, Wallner M, Lingenhel G et al (2013) Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant 28:1232–1240PubMed
73.
Zitt E, Rix M, Urena Torres P, Fouque D, Jacobson SH, Petavy F et al (2011) Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study. Nephrol Dial Transplant 26(6):1956–1961. https://​doi.​org/​10.​1093/​ndt/​gfq641 CrossRefPubMed
74.
Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y (2004) Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 19:1281–1287PubMed
Metadaten
Titel
Moderne Behandlungsoptionen des sekundären Hyperparathyreoidismus vor dem Hintergrund kardiovaskulärer Kalzifizierung
verfasst von
OA PD Dr. Emanuel Zitt
Publikationsdatum
07.02.2020
Verlag
Springer Vienna
Erschienen in
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 2/2020
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI
https://doi.org/10.1007/s41970-020-00098-7

Weitere Artikel der Ausgabe 2/2020

Mitteilungen des Magnesiumforum Bad Radkersburg

  • Mitteilungen des Magnesiumforum Bad Radkersburg

News-Screen Orthopädie & Traumatologie

  • News-Screen Orthopädie & Traumatologie

Editorial

  • Editorial

Rheuma und Gastroenterologie

  • Originalien

Mitteilungen der ÖGKM

  • Mitteilungen der ÖGKM

Rheuma und Knochenstoffwechsel